- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04285567
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Reference Study ID Number: CO41685 https://forpatients.roche.com/
- Phone Number: 888-662-6728 (U.S. Only)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
Australian Capital Territory
-
Canberra, Australian Capital Territory, Australia, 2605
- Canberra Hospital; Haematology Department
-
-
New South Wales
-
Liverpool, New South Wales, Australia, 2170
- Liverpool Hospital; Haematology
-
Port Macquarie, New South Wales, Australia, 2444
- Port Macquarie Base Hospital
-
St. Leonards, New South Wales, Australia, 2065
- Royal North Shore Hospital; Haematology Department
-
-
Tasmania
-
Hobart, Tasmania, Australia, 7000
- Royal Hobart Hospital
-
-
Victoria
-
Epping, Victoria, Australia, VIC 3076
- The Northern Hospital
-
Melbourne, Victoria, Australia, 3168
- Monash Medical Centre; Haematology
-
Melbourne, Victoria, Australia, 3002
- Peter MacCallum Cancer Centre; Department of Haematology
-
-
-
-
-
Caen, France, 14033
- CHU de Caen, Institut d'Hématologie de Basse-Normandie
-
Creteil, France, 94010
- Hopital Henri Mondor; Hematologie Clinique
-
Le Mans, France, 72000
- Clinique Victor Hugo- CCS du Mans
-
Lille, France, 59037
- CHRU Lille - Hôpital Claude Huriez; Service des Maladies du Sang
-
Perpignan, France, 66046
- Hopital Saint Jean : Pole Santé du Rousillon; Unité de Recherche clinique
-
Pessac, France, 33604
- Hopital De Haut Leveque; Hematologie Clinique
-
Pierre Benite, France, 69495
- Ch Lyon Sud; Hemato Secteur Jules Courmont
-
Poitiers, France, 86021
- Hopital De La Miletrie; Hematologie Et Oncologie Medicale
-
Reims, France, 51092
- Hopital Robert Debre; Hematologie Clinique
-
TOURS Cedex, France, 37044
- Hopital Bretonneau; Hematologie Therapie Cellulaire
-
Toulon, France, 83056
- CHI de Toulon - Hôpital Sainte Musse
-
-
-
-
Emilia-Romagna
-
Modena, Emilia-Romagna, Italy, 41123
- Azienda Ospedaliero-Universitaria Policlinico di Modena Ematologia
-
-
Lazio
-
Roma, Lazio, Italy, 00168
- Uni Cattolica; Divisione Di Ematologia
-
Roma, Lazio, Italy, 00161
- Universita' Degli Studi La Sapienza-Ist.Di Ematologia; Dip Biot Cel e Ematol
-
-
Liguria
-
Genova, Liguria, Italy, 16132
- A.O. Universitaria S. Martino Di Genova; Ematologia 1
-
-
Lombardia
-
Milano, Lombardia, Italy, 20122
- Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
-
Milano, Lombardia, Italy, 20162
- ASST GRANDE OSPEDALE METROPOLITANO NIGUARDA; Struttura Complessa di Ematologia
-
-
Piemonte
-
Novara, Piemonte, Italy, 28100
- SCDU Ematologia
-
-
Puglia
-
Bari, Puglia, Italy, 70124
- Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
-
Lecce, Puglia, Italy, 73100
- Asl Le-Ospedale "Vito Fazzi";U.O. Ematologia
-
-
Umbria
-
Sant'Andrea Delle Fratte (PG), Umbria, Italy, 06132
- Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
-
-
-
-
-
Madrid, Spain, 28046
- Hospital Universitario la Paz; Servicio de Hematologia
-
Murcia, Spain, 30008
- Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología
-
Sevilla, Spain, 41013
- Hospital Universitario Virgen del Rocio; Servicio de Hematologia
-
Toledo, Spain, 45007
- Hospital Universitario de Toledo
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08915
- Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Hospital de Navarra, Servicio de Hematología
-
-
Tenerife
-
La Laguna, Tenerife, Spain, 38320
- Hospital Universitario de Canarias;servicio de Hematologia
-
-
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Medical Center of Aurora; Rocky Mountain Cancer Centers
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Center for Cancer and Blood Disorders
-
Columbia, Maryland, United States, 21044
- Maryland Oncology Hematology, P.A.
-
-
Montana
-
Billings, Montana, United States, 59102
- St. Vincent Frontier Cancer Center
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- University of Tennessee Medical Center
-
-
Texas
-
Amarillo, Texas, United States, 79106
- Texas Oncology West
-
Austin, Texas, United States, 78705
- Southwest Regional Cancer Center
-
Denton, Texas, United States, 76201
- Texas Oncology-Denton South
-
McAllen, Texas, United States, 78503
- South Texas Cancer Center - McAllen
-
Tyler, Texas, United States, 75702
- Texas Oncology- Northeast Texas
-
-
Utah
-
Ogden, Utah, United States, 84405
- Community Cancer Trials of Utah
-
-
Virginia
-
Roanoke, Virginia, United States, 24014
- Oncology & Hematolgy Associates of SW Va Inc. - Roanoke
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to comply with the study protocol, in the investigator's judgment
- Aged 18 years or older
- Have previously untreated documented Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
- CLL requiring treatment according to the iwCLL criteria
- Cumulative Illness Rating Scale (CIRS) score ≤ 6 and creatinine clearance (CrCl) ≥ 70 mL/min
Hematology values within the following limits, unless cytopenia is caused by the underlying disease (i.e., no evidence of additional bone marrow (BM) dysfunction; e.g., myelodysplastic syndrome, hypoplastic BM):
- Absolute neutrophil count ≥ 1.0 x 109/L, unless there is BM involvement
- Platelet count ≥ 75 x 109/L and more than 7 days since last transfusion, or ≥ 30 x 109/L if there is BM involvement
- Adequate liver function as indicated by a total bilirubin, aspartate aminotransferase, and Alanine transaminase ≤ 2 times the institutional upper limit of normal (ULN) value, unless directly attributable to the participant's CLL
- Life expectancy >6 months
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm
Exclusion Criteria:
- Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL)
- Participants with Small Lymphocyclic Lymphoma (SLL) only
- Known central nervous system involvement
- Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)
- Detected del(17p) or TP53 mutation (valid test within 6-months from screening is required for randomisation)
- An individual organ/system impairment score of 4 as assessed by the Cumulative Illness Rating Scale (CIRS) definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system
- Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
- History of prior malignancy
- Participants with infections requiring IV treatment (Grade 3 or 4) within the last 8 weeks prior to enrollment
- Evidence of other clinically significant uncontrolled conditions including but not limited to active or uncontrolled systemic infection (e.g., viral, bacterial, or fungal)
- History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
- Hypersensitivity to fludarabine, bendamustine, cyclophosphamide, rituximab, obinutuzumab, or venetoclax or to any of the excipients (e.g., trehalose)
- Pregnant women and nursing mothers
- Vaccination with a live vaccine ≤ 28 days prior to randomization
- Prisoners or participants who are institutionalized by regulatory or court order or persons who are in dependence to the Sponsor or an investigator
- History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
- Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology)
- Positive test result for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
- Participants with known infection with HIV or Human T-Cell Leukemia Virus 1 (HTLV-1)
- Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study
Received any of the following agents within 28 days prior to the first dose of study treatment:
- Immunotherapy
- Radiotherapy
- Hormone therapy
- Any therapies intended for the treatment of lymphoma/leukemia whether approved or experimental
Participants who have received the following agents:
- Strong and moderate CYP3A inhibitors/inducers within 7 days prior to the initiation of study treatment
- Steroid therapy for anti-neoplastic intent with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids within 7 days prior to the first dose of study drug administration
- Consumed grapefruit, grapefruit products, Seville oranges(including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug and throughout venetoclax administration
- Inability to swallow a large number of tablets.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VEN + G
Participants will receive 12 cycles of treatment (each cycle is 28 days).
Venetoclax (VEN) will be administered orally, daily, with a 5-week ramp-up period, starting on Cycle 1, Day 22 and administration will continue until the end of Cycle 12. Obinutuzumab (G) will be administered intravenously (IV) on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
|
Venetoclax 20 mg will be administered orally, once daily starting on Day 22 of Cycle 1 for 7 days, then ramp up from 50 to 400 mg/day during Cycle 2 and continue at 400 mg/day from Day 1 of Cycle 3 till end of Cycle 12.
Other Names:
Obinutuzumab 1000 milligrams (mg) will be administered IV on Days 1 (and 2), 8, and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
Other Names:
|
Active Comparator: FCR/BR
Participants will receive 6 cycles of Fludarabine + Cyclophosphamide + Rituximab (FCR) consisting of a single cycle of a single infusion of rituximab on Day 1 and fludarabine and cyclophosphamide infusions on Days 1-3 of each 28-day cycle or bendamustine (B) as infusions on Days 1 and 2 and a single cycle of rituximab on Day 1 of each 28-day cycle.
|
Fludarabine will be administered in a dosage of 25 milligram per meter squared (mg/m^2), IV, on days 1, 2, and 3 of Cycles 1-6.
Cyclophosphamide will be administered in a dosage of 250 mg/m^2, IV, on Days 1, 2, and 3 Cycles 1-6.
Rituximab will be administered at a dose of 375 mg/m^2, IV, on Cycle 1, Day 1 followed by 500 mg/m^2 on Day 1 of Cycles 2-6.
Other Names:
Bendamustine will be administered at a dose of 90 mg/m^2, IV, on 2 consecutive days of Cycles 1-6.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Minimal Residual Disease (MRD) Response Rate Using Next-generation Sequencing (NGS)
Time Frame: At Month 15
|
At Month 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRD Response Rate in Peripheral Blood (PB) at the End of Treatment Response Visit
Time Frame: At end of treatment response visit (up to approximately 15 months in Arm VEN + G and 9 months in Arm FCR/BR
|
At end of treatment response visit (up to approximately 15 months in Arm VEN + G and 9 months in Arm FCR/BR
|
|
MRD Response Rate in Bone Marrow (BM) at the End of Treatment Response Visit
Time Frame: At end of treatment response visit (up to approximately 15 months in Arm VEN + G and 9 months in Arm FCR/BR
|
At end of treatment response visit (up to approximately 15 months in Arm VEN + G and 9 months in Arm FCR/BR
|
|
Objective Response Rate (ORR)
Time Frame: At Month 15
|
At Month 15
|
|
Complete Response (CR) Rate
Time Frame: At Month 15
|
At Month 15
|
|
MRD Response Rate in PB of Participant With a CR/CR With Incomplete Blood Count (CRi) at Month 15
Time Frame: At Month 15
|
At Month 15
|
|
MRD Response Rate in the BM of Participants With a CR/CRi at the End of Treatment Visit
Time Frame: At end of treatment response visit (up to approximately 15 months in Arm VEN + G and 9 months in Arm FCR/BR
|
At end of treatment response visit (up to approximately 15 months in Arm VEN + G and 9 months in Arm FCR/BR
|
|
Best Overall Response
Time Frame: Up to and including the assessment at Month 15
|
Up to and including the assessment at Month 15
|
|
Progression-free Survival (PFS)
Time Frame: From randomization up to the first occurrence of disease progression (PD), or death from any cause (up to 74 months)
|
From randomization up to the first occurrence of disease progression (PD), or death from any cause (up to 74 months)
|
|
Duration of Objective Response (DOR)
Time Frame: From time of first response until PD, or death from any cause (up to 74 months)
|
From time of first response until PD, or death from any cause (up to 74 months)
|
|
Event-free Survival (EFS)
Time Frame: From randomization up to PD /relapse, death, or start of a new anti-leukemic therapy (up to 74 months)
|
From randomization up to PD /relapse, death, or start of a new anti-leukemic therapy (up to 74 months)
|
|
Overall Survival (OS)
Time Frame: From randomization up to death due to any cause (up to 74 months)
|
From randomization up to death due to any cause (up to 74 months)
|
|
Arm VEN + G: Tumor Lysis Syndrome (TLS) Risk Reduction Rate
Time Frame: At screening and Cycle 1 Day 22 (cycle length= 28 days)
|
At screening and Cycle 1 Day 22 (cycle length= 28 days)
|
|
Arm VEN + G: Reduction in Mandatory Hospitalisations During Venetoclax Ramp-up
Time Frame: On Cycle 1 Day 22 (cycle length= 28 days)
|
On Cycle 1 Day 22 (cycle length= 28 days)
|
|
Change From Baseline in M.D. Anderson Symptom Inventory-CLL (MDASI-CLL) Score
Time Frame: Arm VEN + G: Day 1 of Cycle 1-12, Day 28 after treatment completion/early termination (TC/ET), follow up (FU) visits; Arm FCR/BR: Day 1 of Cycle 1-6, Day 28 after TC/ET, end of combination treatment response visit and FU visit (up to 74 months)
|
The MDASI-CLL is a questionnaire of 25 items related to CLL specific symptoms that a participant may have experienced in the past 24 hours.
Participants were asked to rate the severity of 13 symptoms called mean core symptom severity (i.e., pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, and numbness or tingling), 6 disease-specific symptoms called mean module symptom severity (night sweats, fevers and chills, lymph node swelling, diarrhea, easy bruising or bleeding, and constipation) and 6 mean interference on life questions (i.e., general activity, walking, work, mood, relations with other people, and enjoyment of life) on a scale from 0 to 10 with 0 indicating that the symptom is "not present" or "did not interfere" with the participant's activities and 10 indicating "as bad as you can imagine" or "interfered completely".
|
Arm VEN + G: Day 1 of Cycle 1-12, Day 28 after treatment completion/early termination (TC/ET), follow up (FU) visits; Arm FCR/BR: Day 1 of Cycle 1-6, Day 28 after TC/ET, end of combination treatment response visit and FU visit (up to 74 months)
|
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQC-30)
Time Frame: Arm VEN + G: Day 1 of Cycle 1-12, Day 28 after treatment completion/early termination (TC/ET), follow up (FU) visits; Arm FCR/BR: Day 1 of Cycle 1-6, Day 28 after TC/ET, end of combination treatment response visit and FU visit (up to 74 months)
|
The EORTC QLQ-C30 is a validated and reliable self-report measure consisting of 30 questions incorporated into five functional scales (physical, role, cognitive, emotional, and social scales), three symptom scales (fatigue, pain, nausea, and vomiting scales), and a global health status/global quality-of-life scale.
The remaining single items (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) assess the additional symptoms experienced by patients with cancer and the perceived financial burden of treatment.
The 28 function and symptom items were scored on a 4-point scale that ranged from "not at all" to "very much," and the 2 global health status/global quality-of-life items were scored on a 7-point scale that ranged from "very poor" to "excellent."
Raw average scale scores were linearly transformed to range 0-100 with higher scores indicating higher response levels (i.e., higher functioning, higher symptom severity).
|
Arm VEN + G: Day 1 of Cycle 1-12, Day 28 after treatment completion/early termination (TC/ET), follow up (FU) visits; Arm FCR/BR: Day 1 of Cycle 1-6, Day 28 after TC/ET, end of combination treatment response visit and FU visit (up to 74 months)
|
Number of Participants With Adverse Events (AEs)
Time Frame: Up to 28 days after last dose of study drug or until initiation of another anti-cancer therapy (up to 74 months)
|
Up to 28 days after last dose of study drug or until initiation of another anti-cancer therapy (up to 74 months)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial, Hoffmann-La Roche
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Disease Attributes
- Hematologic Diseases
- Leukemia, B-Cell
- Chronic Disease
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Immunological
- Cyclophosphamide
- Venetoclax
- Bendamustine Hydrochloride
- Rituximab
- Fludarabine
- Obinutuzumab
Other Study ID Numbers
- CO41685
- 2019-003327-37 (EudraCT Number)
- 2023-504036-17-00 (Other Identifier: EU CT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/innovation/process/clinical-trials/data-sharing).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Lymphocytic Leukemia (CLL)
-
AbbVieRecruitingCancer, Chronic Lymphocytic Leukemia (CLL)Korea, Republic of
-
Hackensack Meridian HealthCelgene CorporationTerminatedSmall Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia(CLL)United States
-
Piramal Enterprises LimitedDana-Farber Cancer Institute; Norris Cotton Cancer CenterSuspendedRelapsed/Refractory Chronic Lymphocytic Leukemia (CLL)United States
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Tampere University HospitalCompleted
-
AstraZenecaRecruitingChronic Lymphocytic Leukaemia (CLL)Germany
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.WithdrawnChronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | CLL/SLL | SLLUnited States
-
University of California, IrvineUnited States Department of DefenseActive, not recruitingAcute Myeloid Leukemia | Chronic Lymphocytic Leukemia | AML, Adult | CLL | CLL, Relapsed | CLL, RefractoryUnited States
-
Novartis PharmaceuticalsCompletedChronic Lymphocytic Leukemia (CLL) | Leukaemia, Lymphocytic, ChronicUnited States, Belgium, Italy, Greece, Russian Federation, Spain, Poland, Czech Republic
-
AstraZenecaCLL ConsortiumCompletedB Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)United States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
BioSight Ltd.Recruiting
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Lymphocytic LeukemiaUnited States